Chiesi Group

Chiesi is an international, research-focused biopharmaceutical group that develops and markets innovative therapeutic solutions for respiratory diseases, rare diseases, and hospital care.

We see our mission as improving people’s quality of life while acting responsibly for the benefit of society and the environment. By changing its legal status to a Benefit Corporation in countries where this is possible (Italy, the United States, and France), Chiesi has made its commitment to creating shared value for society as a whole legally binding.

Since 2019, Chiesi has been a certified B Corp, meaning that our business practices meet verified social and environmental standards. The company aims to achieve net-zero emissions (Scope 1–3) by 2035.

With over 90 years of experience, Chiesi is headquartered in Parma (Italy) and operates in 31 countries with more than 7,500 employees. In 2024, the company generated revenues of €3.4 billion, approximately 24% of which was reinvested in research and development. The Group’s main R&D center is located in Parma, alongside six additional R&D centers in France, the United States, Canada, China, the United Kingdom, and Sweden.

For further information: www.chiesi.com